Abarelix

Abarelix

Clinical data
ATC code	L02BX01 (WHO)
Pharmacokinetic data
Protein binding	96–99%
Identifiers
IUPAC name acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
CAS Number	183552-38-7
PubChem CID	16131215
DrugBank	BTD00051
CompTox Dashboard (EPA)	DTXSID20171443
Chemical and physical data
Formula	C72H95ClN14O14
Molar mass	1416.06 g/mol g·mol−1

Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.

More information can be found at Plenaxis.de [1] and FastProstateControl.com [2].